,  том 11 ,  издание 1 ,  страницы 74-84

Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies

Тип публикации: Journal Article
Дата публикации: 2014-01-27
SCImago Q3
БС2
SJR: 0.353
CiteScore: 2.9
Impact factor: —
ISSN: 15701638, 18756220
Drug Discovery
Краткое описание
Transgenic mice have yielded seven of the ten currently-approved human antibody drugs, making them the most successful platform for the discovery of fully human antibody therapeutics. The use of the in vivo immune system helps drive this success by taking advantage of the natural selection process that produces antibodies with desirable characteristics. Appropriately genetically-engineered mice act as robust engines for the generation of diverse repertoires of affinity- matured fully human variable regions with intrinsic properties necessary for successful antibody drug development including high potency, specificity, manufacturability, solubility and low risk of immunogenicity. A broad range of mAb drug targets are addressable in these mice, comprising both secreted and transmembrane targets, including membrane multi-spanning targets, as well as human target antigens that share high sequence identity with their mouse orthologue. Transgenic mice can routinely yield antibodies with sub-nanomolar binding affinity for their antigen, with lead candidate mAbs frequently possessing affinities for binding to their target of less than 100 picomolar, without requiring any ex vivo affinity optimization. While the originator transgenic mice platforms are no longer broadly available, a new generation of transgenic platforms is in development for discovery of the next wave of human therapeutic antibodies.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

1
2
3
4
5
bioRxiv
5 публикаций, 11.11%
mAbs
4 публикации, 8.89%
Frontiers in Immunology
2 публикации, 4.44%
Proceedings of the National Academy of Sciences of the United States of America
2 публикации, 4.44%
Journal of Immunology
1 публикация, 2.22%
Biomedicines
1 публикация, 2.22%
Viruses
1 публикация, 2.22%
BioDrugs
1 публикация, 2.22%
Archivum Immunologiae et Therapiae Experimentalis
1 публикация, 2.22%
Scientific Reports
1 публикация, 2.22%
Russian Chemical Reviews
1 публикация, 2.22%
PLoS ONE
1 публикация, 2.22%
Current Opinion in Microbiology
1 публикация, 2.22%
Journal of Controlled Release
1 публикация, 2.22%
Immunology Letters
1 публикация, 2.22%
Immunological Reviews
1 публикация, 2.22%
Journal of Labelled Compounds and Radiopharmaceuticals
1 публикация, 2.22%
eLife
1 публикация, 2.22%
Lipophilicity in Drug Action and Toxicology
1 публикация, 2.22%
Advances in Experimental Medicine and Biology
1 публикация, 2.22%
ACS Symposium Series
1 публикация, 2.22%
Introduction to Insect Biotechnology
1 публикация, 2.22%
Methods in Molecular Biology
1 публикация, 2.22%
Brazilian Journal of Pharmaceutical Sciences
1 публикация, 2.22%
Handbook of Experimental Pharmacology
1 публикация, 2.22%
Current Topics in Microbiology and Immunology
1 публикация, 2.22%
Toxicon: X
1 публикация, 2.22%
Human Gene Therapy
1 публикация, 2.22%
Journal of Biochemical and Molecular Toxicology
1 публикация, 2.22%
1
2
3
4
5

Издатели

1
2
3
4
5
6
7
8
Springer Nature
8 публикаций, 17.78%
Elsevier
7 публикаций, 15.56%
Wiley
7 публикаций, 15.56%
openRxiv
5 публикаций, 11.11%
Taylor & Francis
4 публикации, 8.89%
MDPI
2 публикации, 4.44%
Frontiers Media S.A.
2 публикации, 4.44%
Proceedings of the National Academy of Sciences (PNAS)
2 публикации, 4.44%
The American Association of Immunologists
1 публикация, 2.22%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 2.22%
Public Library of Science (PLoS)
1 публикация, 2.22%
eLife Sciences Publications
1 публикация, 2.22%
American Chemical Society (ACS)
1 публикация, 2.22%
1 публикация, 2.22%
Mary Ann Liebert
1 публикация, 2.22%
Society of Nuclear Medicine
1 публикация, 2.22%
1
2
3
4
5
6
7
8
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
45
Поделиться
Цитировать
ГОСТ |
Цитировать
Green L. Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies // Current Drug Discovery Technologies. 2014. Vol. 11. No. 1. pp. 74-84.
ГОСТ со всеми авторами (до 50) Скопировать
Green L. Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies // Current Drug Discovery Technologies. 2014. Vol. 11. No. 1. pp. 74-84.
RIS |
Цитировать
TY - JOUR
DO - 10.2174/15701638113109990038
UR - https://doi.org/10.2174/15701638113109990038
TI - Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies
T2 - Current Drug Discovery Technologies
AU - Green, Larry
PY - 2014
DA - 2014/01/27
PB - Bentham Science Publishers Ltd.
SP - 74-84
IS - 1
VL - 11
PMID - 23978036
SN - 1570-1638
SN - 1875-6220
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2014_Green,
author = {Larry Green},
title = {Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies},
journal = {Current Drug Discovery Technologies},
year = {2014},
volume = {11},
publisher = {Bentham Science Publishers Ltd.},
month = {jan},
url = {https://doi.org/10.2174/15701638113109990038},
number = {1},
pages = {74--84},
doi = {10.2174/15701638113109990038}
}
MLA
Цитировать
Green, Larry. “Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal Antibodies.” Current Drug Discovery Technologies, vol. 11, no. 1, Jan. 2014, pp. 74-84. https://doi.org/10.2174/15701638113109990038.
Ошибка в публикации?